Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1992-8-31
|
pubmed:abstractText |
Due to rapid clearance of interleukin-2 (IL-2), it has had limited effective use as an in vivo immunostimulant. Current experimental and clinical protocols generally must utilize large doses, multiple injections, or continuous infusions of IL-2 in order to achieve significant immunostimulation, often at the expense of systemic toxicity. Therefore, the pharmacodynamics of IL-2 liposomes were investigated. IL-2 liposome incorporation efficiency was 80.4% (SD 5.5); vesicle diameter was 1.65 microns (SD 0.09) as determined by fluorescence-activated cell sorting (FACS). Both formulation (free cytokine vs. IL-2 liposomes) and route of administration were important variables in determination of the biodistribution and pharmacokinetic characteristics of IL-2. When free [125I]IL-2 was given i.v. to mice, only 6.5% was in the blood and 3% in liver and spleen 2 h after injection; on the other hand, at 2 h greater than 70% of i.v. [125I]IL-2 liposomes were detected in the blood, liver, spleen, and lungs. Mean i.v. elimination t1/2 from the blood of rats given 20 x 10(6) U/kg free cytokine or IL-2 liposomes was 41 versus 102 min, respectively, as measured by bioassay and 59 and 119 min as measured by enzyme immunoassay (EIA). After i.v. administration, the estimated Vd of IL-2 liposomes was 13-fold smaller than the free cytokine. Intrathoracic (i.tx.), i.p., and s.c. administration of [125I]IL-2 to mice also demonstrated significant depot effects when IL-2 was incorporated into liposomes. These data suggest IL-2 liposomes may provide in vivo immunostimulation superior to the free cytokine due to biodistribution and depot characteristics.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Delayed-Action Preparations,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Carriers,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Iodine Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Liposomes,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1053-8550
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
19-31
|
pubmed:dateRevised |
2008-3-18
|
pubmed:meshHeading |
pubmed-meshheading:1637781-Animals,
pubmed-meshheading:1637781-Cell Line,
pubmed-meshheading:1637781-Delayed-Action Preparations,
pubmed-meshheading:1637781-Drug Carriers,
pubmed-meshheading:1637781-Female,
pubmed-meshheading:1637781-Immunoenzyme Techniques,
pubmed-meshheading:1637781-Injections, Intraperitoneal,
pubmed-meshheading:1637781-Injections, Intravenous,
pubmed-meshheading:1637781-Injections, Subcutaneous,
pubmed-meshheading:1637781-Interleukin-2,
pubmed-meshheading:1637781-Iodine Radioisotopes,
pubmed-meshheading:1637781-Liposomes,
pubmed-meshheading:1637781-Mice,
pubmed-meshheading:1637781-Mice, Inbred C57BL,
pubmed-meshheading:1637781-Recombinant Proteins,
pubmed-meshheading:1637781-Thorax,
pubmed-meshheading:1637781-Tissue Distribution
|
pubmed:year |
1992
|
pubmed:articleTitle |
Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration.
|
pubmed:affiliation |
Department of Pediatrics, University of Minnesota, Minneapolis 55455.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|